Business
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company
About this update from Immatics N.v.
[{"type":"text","content":"Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming oral and poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer in Houston, Texas from November 6 - 10, 2024. Full abstracts will be available on November 5, 2024, at 9:00 am EST in the JITC Supplement. Oral Presentations Date / Time: November 8, 2024 / 3:50 – 5:25 pm Central Standard TimeSession: Oral Abstract Session 1Abstract Number: 687Title: ACTengine IMA203 TCR-T targeting PRAME shows deep and durable anti-tumor activity in heavily pretreated solid cancer patients Presenter: Martin Wermke, M.D. (University Hospital Dresden, Germany) Date / Time: November 9, 2024 / 12:30 PM - 1:30 pm Central Standard TimeSession: Rapid Oral - Clinical 2Abstract Number: 661Title: Enhanced pharmacology data of next-generation IMA203CD8 TCR-T monotherapy targeting PRAMEPresenter: Dejka M. Araujo, M.D. (MD Anderson Cancer Center, Houston, Texas, USA) Poster Presentations Date: November 8, 2024 Poster Number: 355 Title: An approach to bridging starting materials to monitor T cell persistence in adoptive T cell therapyPresenter: Jourdan Andersson, Ph.D. (Immatics) Date: November 9, 2024 Poster Number: 226 Title: An effective donor screening program for manufacturing of allogeneic γδ T cell productsPresenter: Inbar Azoulay Alfaguter, Ph.D. (Immatics) Date: November 9, 2024 Poster Number: 228 Title: Optimizing and streamlining the manufacturing of Vγ9Vδ2 γδ T cells for allogeneic therapyPresenter: Pooja Mehta, Ph.D. (Immatics) Date: November 9, 2024 Abstract Number: 360 Title: Combination of a TCR-engineered autologous PRAME-targeting T cell therapy with a PRAME-encoding mRNA for the treatment of solid tumorsPresenter: Fabian Brunk, Ph.D. (Immatics) Date: November 9, 2024 Poster Number: 372 Title: TCR-engineered T cells exhibit enhanced persistence and serial killing ability when armored with membrane-bound IL-15Presenter: Justin Gunesch, Ph.D. (Immatics) About IMA203 and Target PRAMEACTengine® IMA203 T cells are directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma (PRAME), a protein frequently ex...